Table 1 Baseline characteristics of RCC and BC patients

From: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

Baseline characteristics

RCC patients (n=39)

BC patients (n=34)

Mean age (years)

65.1 (43–82)

64.4 (44–77)

Sex (%)

Men

69.2

85.3

Women

30.8

14.7

ECOG performance status (%)

0

21.1

18.8

1

47.4

40.6

2

21.1

28.1

3

10.5

9.4

4

0

3.1

TNM stage (%)

I

0

6.7

II

5.7

16.7

III

34.3

6.7

IV

60

70

Previous surgery (%)

87.2

85.3

Mean time since bone metastases diagnosed (months)

6.2 (0–59.1)

2.4 (0–34.6)

Previous SRE (%)

56.4

50

Analgesic treatment (%)

84.6

94.1

Antineoplasic treatment (%)

Chemotherapy

5.1

29.4

Antiangiogenic

61.5

2.9

mTOR inhibitors

20.5

0

Radiotherapy (%)

30.8

32.4

  1. Abbreviations: BC=bladder cancer; ECOG=Eastern Cooperative Oncology Group; mTOR=mammalian target of rapamycin; RCC=renal cell carcinoma; SRE=skeletal-related events; TNM=tumour, nodes, metastasis.
Back to article page